NCT02791516View on ClinicalTrials.gov

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

February 12, 2018

Study Completion Date

December 21, 2018

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Romosozumab

Administered by subcutaneous injection once a month (QM)

DRUG

Placebo

Administered by subcutaneous injections once a month

Trial Locations (10)

21565

Research Site, Namdong-gu, Incheon

602-739

Research Site, Busan

501-757

Research Site, Gwangju

463-707

Research Site, Seongnam Si Gyeonggi Do

120-752

Research Site, Seoul

135-710

Research Site, Seoul

136-705

Research Site, Seoul

138-736

Research Site, Seoul

150-713

Research Site, Seoul

443-380

Research Site, Suwon-si, Gyeonggi-do

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02791516 - A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis | Biotech Hunter | Biotech Hunter